Skye Licenses Halozyme's ENHANZE Drug Delivery Technology For Obesity Treatment

Core Viewpoint - Halozyme Therapeutics, Inc. has entered into a global collaboration and license agreement with Skye Bioscience, Inc. to develop and commercialize higher-dose, subcutaneous administration strategies for nimacimab, targeting the obesity market [1] Group 1: Agreement Details - Skye Bioscience has licensed Halozyme's ENHANZE drug delivery technology to expand its application in the obesity market [1] - Skye plans to evaluate multiple dose-ranging strategies for nimacimab, including combinations with GLP-1 receptor agonists [2] - The agreement includes milestone payments from Skye to Halozyme based on the achievement of specific development and commercialization events [2] Group 2: Financial Terms and Future Plans - Halozyme will receive mid-single digit royalties on net sales of nimacimab developed with ENHANZE for a minimum of 10 years [3] - Skye intends to initiate a Phase 2b clinical trial for nimacimab with ENHANZE in obesity by mid-2026 [3] - In pre-market trading, HALO shares are priced at $70.46, reflecting a 0.21% increase, while SKYE shares are at $0.97, showing an 11.44% increase [3]